

厚生労働科学研究費補助金（肝炎等克服緊急対策研究事業）
分担研究報告書（平成23年度）

B型肝炎ウイルス感染の病態別における宿主因子等について、網羅的な遺伝子解析を用い、新規診断法及び治療法の開発を行う研究

分担研究者：田中 靖人 名古屋市立大学 大学院医学研究科 教授
研究協力者：松浦健太郎 名古屋市立大学 大学院医学研究科 臨床研究医
村上 周子 名古屋市立大学 大学院医学研究科 助教

分担研究課題：ウイルスマーカーの臨床的有効性評価

研究要旨：全国多施設共同研究により、HBs抗原陽性の肝がん患者79例と、年齢を一致させた非肝がん患者（無症候性キャリア、慢性肝炎）77例をコントロールとして、ウイルス遺伝子解析を行った。結果：男性の割合、genotype Cの割合、C1653T変異及びA1762T/G1764A変異が肝がん患者で有意に高かった($p<0.01$)。これらは、従来から肝がんとの関連性が報告されているウイルス変異で、今後は宿主因子と組み合わせることで、より精度の高い診断が期待される。

A. 研究目的

本研究班の目的は、B型肝炎ウイルス感染に起因する各種の病態形成に関わる宿主（ヒト）因子を網羅的ゲノム解析により同定し、新たな診断法や治療法の開発に寄与することにある。分担研究として、同一個体内でのウイルスゲノムの解析や遺伝子機能解析も実施することにより、各種病態形成に関わる宿主遺伝要因間や宿主遺伝要因とウイルス因子間の相互作用も明らかにすることである。

B. 研究方法

全国多施設共同研究により、検体とその検体についての臨床データおよび患者様情報（付帯情報）の収集を行った。各施設において検体とデータは、連結可能な匿名化を行った上で提出頂いた。HBs抗原陽性の肝がん患者79例検体と、年齢を一致させた非肝がん患者（無症候性キャリア、慢性肝炎）77例をコントロールとして、ウイルス遺伝子解析を行った。Genotype Cの割合、C1653T変異及びA1762T/G1764A変異が肝がん患者で有意に高かった($p<0.01$)。

（倫理面への配慮）

ヒト由来試料の解析にあたり、新規試料については必ずインフォームドコンセントを取得し、既存試料についてはインフォームドコンセントの取得されたもののみを取り扱い、解析データの公表に際しては個人情報保護を徹底する。

C. 研究結果

HBs抗原陽性の肝がん患者79例と、年齢を一致させた非肝がん患者（無症候性キャリア、慢性肝炎）77例をコントロールとして、ウイルス遺伝子解析を行った。Genotype Cの割合、C1653T変異及びA1762T/G1764A変異が肝がん患者で有意に高かった($p<0.01$)。

D. 考察

従来から報告されているC1653T変異及びA1762T/G1764A変異が肝がん患者で有意に高かった。今後は宿主因子と組み合わせることで、より精度の高い診断が期待される。

E. 結論

今回の日本人集団において、肝がんに関連するウイルス変異が同定された。

F. 研究発表

1. 論文発表

1. Sa-Nguanmoo P, Tanaka Y, Ratanakorn P, Sugiyama M, Murakami S, Payungporn S, Sommanustweechai A, Mizokami M, Poovorawan Y. Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes. *Virus Res.* 2011;158(1-2):209-15.
2. Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M. Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. *Hepatol Res.* 2011;41(6):505-511.
3. Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsuhashi H, Nagacka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. *Hepatol Res.* 2012 ;42(2):139-149.

2. 学会発表

1. Tanaka Y. Progress in technology for diagnosis and treatment monitoring. The 17th Annual Meeting of the Korean Association for the Study of the Liver. Changing Concepts of Chronic Hepatitis B. June 9-11, 2011. Seoul, Korea.
2. Sugauchi F, Tanaka Y, Matsuura K, Watanabe T, Tajiri K, Kishi H, Masashi M. CROSS-GENOTYPE PROTECTION OF HBV AND A ROLE OF HBS ANTIGEN MUTATION IN IMMUNITY ESCAPE IN VITRO AND IN VIVO MODEL USING UPA/SCID MICE WITH HUMAN HEPATOCYTES. THE 62ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF

LIVER DISEASES. NOV 4-8,2011.San Francisco.

3. .Sugiyama M, Tanaka Y, Nakanishi M, Sudoh M, Mizokami M. HOST SPHINGOLIPID BIOSYNTHESIS AS A THERAPEUTIC TARGET FOR HEPATITIS B VIRUS REPLICATIONTHE 62ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES.NOV 4-8,2011.San Francisco.
4. 新海登、田中靖人、日下部篤宣、松浦健太郎、溝上雅史. 分子診断を含めた抗原・抗体検査による消化器がん検診のありかた B型肝炎関連肝癌の囲い込みウイルス変異及びHBV関連マーカーを用いて.日本消化器がん検診学会. 平成23年5月20日～22日.東京.
5. 木村達治、小林万利子、田中靖人、溝上雅史、熊田博光.「イムニス HBV ゲノタイプEIA」の臨床性能.第47回日本肝臓学会総会.2011年6月2日～3日. 東京.
6. 今関文夫、呉 霜、神田達郎、田中靖人、横須賀收. HBe 抗原・抗体とB型肝炎ウイルス遺伝子変異の検討.第47回日本肝臓学会総会. 2011年6月2日～3日. 東京.
7. 田尻和人、河合健吾、時光善温、峯村正実、安村 敏、高原照美、杉山敏郎、岸裕幸、村口 篤、田中靖人.エスケープミュータントに対するHBワクチンの作用機序の検討. 第47回日本肝臓学会総会.2011年6月2日～3日. 東京.

G. 知的所得権の出願・登録状況

1. 特許取得
なし
2. 実用新案登録
なし
3. その他
なし

III. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
*Sakamoto N, Nakagawa M, <u>Tanaka Y</u> , Sekine-Osajima Y, Ueyama M, Kurosaki M, <u>Nishida N</u> , Tamori A, Yuki NS, Itsui Y, Azuma S, Kakinuma S, Hige S, Itoh Y, Tanaka E, Hiasa Y, Izumi N, <u>Tokunaga K</u> , <u>Mizokami M</u> , Watanabe M; Ochanomizu-Liver Conference Study Group.	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.	J Med Virol.	83(5)	871-878	2011
* <u>Tanaka Y</u> , Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, <u>Yatsuhashi H</u> , Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, <u>Mochida S</u> , Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, <u>Tokunaga K</u> , <u>Mizokami M</u> .	Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C.	Hum Mol Genet.	20(17)	3507-3516	2011
Kurosaki M, <u>Tanaka Y</u> , Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Matsuura K, Sugauchi F, Enomoto N, <u>Nishida N</u> , <u>Tokunaga K</u> , <u>Mizokami M</u> , Izumi N	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.	Antivir Ther	16(5)	685-694	2011
Ogoshi K, Hashimoto SI, Nakatani Y, Qu W, Oshima K, Tokunaga K, Sugano S, Hattori M, Morishita S, and Matsushima K	Genome-wide profiling of DNA methylation in human cancer cells.	Genomics.	98(4)	280-287	2011
* <u>Nishida N</u> , Mawatari Y, Sageshima M, <u>Tokunaga K</u> .	Highly Parallel and Short-Acting Amplification with Locus-Specific Primers to Detect Single Nucleotide Polymorphisms by the DigiTag2 Assay.	PLoS One.	7(1)	e29967	2012

*Kusakabe A, <u>Tanaka Y</u> , Inoue M, Kurbanov F, Tatematsu K, Nojiri S, Joh T, Tsugane S, <u>Mizokami M.</u>	A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan.	J Gastroenterol	46(1)	117-124	2011
*Wu S, Imazeki F, Kurbanov F, Fukai K, Arai M, Kanda T, Yonemitsu Y, <u>Tanaka Y</u> , <u>Mizokami M.</u> , <u>Yokosuka O.</u>	Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion.	J Hepatol	54(1)	19-25	2011
* <u>Yokosuka O.</u> , Kurosaki M, Imazeki F, Arase Y, <u>Tanaka Y</u> , Chayama K, Tanaka E, Kumada H, Izumi N, <u>Mizokami M</u> , Kudo M.	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009.	Hepatol Res	41(1)	1-21	2011
Gulube Z, Chirara M, Kew M, <u>Tanaka Y</u> , <u>Mizokami M</u> , Kramvis A.	Molecular characterization of hepatitis B virus isolates from Zimbabwean blood donors.	J Med Virol	83(2)	235-244	2011
Sugauchi F, <u>Tanaka Y</u> , Kusumoto S, Matsuura K, Sugiyama M, Kurbanov F, Ueda R, <u>Mizokami M.</u>	Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.	J Med Virol	83(3)	412-418	2011
Yuen MF, Ka-Ho Wong D, Lee CK, <u>Tanaka Y</u> , Allain JP, Fung J, Leung J, Lin CK, Sugiyama M, Sugauchi F, <u>Mizokami M</u> , Lai CL.	Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection.	Clin Infect Dis	52(5)	624-632	2011
Tatematsu K, <u>Tanaka Y</u> , Sugiyama M, Sudoh M, <u>Mizokami M.</u>	Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication.	J Med Virol	83(4)	587-593	2011
*Sugiyama M, Inui A, Shin IT, Komatsu H, Mukaide M, Masaki N, Murata K, Ito K, Nakanishi M, Fujisawa T, <u>Mizokami M.</u>	Easy-to-use phylogenetic analysis system for hepatitis B virus infection.	Hepatol Res	41(10)	936-945	2011
Fukuchi S, Hosoda K, Homma K, <u>Gojobori T</u> , Nishikawa K.	Binary classification of protein molecules into intrinsically disordered and ordered segments.	BMC Struct Biol.	11(1)	1-29	2011

Barrero RA, Keeble-Gagnère G, Zhang B, Moolhuijzen P, Ikeo K, Tateno Y, Gojobori T , Guerrero FD, Lew-Tabor A, Bellgard M.	Evolutionary conserved microRNAs are ubiquitously expressed compared to tick-specific miRNAs in the cattle tick <i>Rhipicephalus</i> (<i>Boophilus</i>) <i>microplus</i> .	BMC Genomics	12(328)	1-17	2011
*Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, Roca J, Agusti A, Brightling C, Cambon-Thomsen A, Cesario A, Abdelhak S, Antonarakis SE, Avignon A, Ballabio A, Baraldi E, Baranov A, Bieber T, Bockaert J, Brahmachari S, Brambilla C, Bringer J, Dauzat M, Ernberg I, Fabbri L, Froguel P, Galas D, Gojobori T , Hunter P, Jorgensen C, Kauffmann F, Kourilsky P, Kowalski ML, Lancet D, Pen CL, Mallet J, Mayosi B, Mercier J, Metspalu A, Nadeau JH, Ninot G, Noble D, Oztürk M, Palkonen S, Préfaut C, Rabe K, Renard E, Roberts RG, Samolinski B, Schünemann HJ, Simon HU, Soares MB, Superti-Furga G, Tegner J, Verjovski-Almeida S, Wellstead P, Wolkenhauer O, Wouters E, Balling R, Brookes AJ, Charron D, Pison C, Chen Z, Hood L, Auffray C.	Systems medicine and integrated care to combat chronic noncommunicable diseases.	Genome Med.	3(7):43	1-12	2011
*Taniya T, Tanaka S, Yamaguchi-Kabata Y, Hanaoka H, Yamasaki C, Maekawa H, Barrero RA, Lenhard B, Datta MW, Shimoyama M, Bumgarner R, Chakraborty R, Hopkinson I, Jia L, Hide W, Auffray C, Minoshima S, Imanishi T, Gojobori T .	A prioritization analysis of disease association by data-mining of functional annotation of human genes.	Genomics	99(1)	1-9	2012

*Kodama Y, Mashima J, Kaminuma E, <u>Gojobori T</u> , Ogasawara O, Takagi T, Okubo K, Nakamura Y.	The DNA Data Bank of Japan launches a new resource, the DDBJ Omics Archive of functional genomics experiments.	Nucleic Acids Res.	40(Database issue)	D38-42	2012
obayashi Y, Suzuki Y, Itou T, Ito F, <u>Gojobori T</u> , and Sakai T.	Evolutionary history of dog rabies in Brazil.	J of General Virology	92	85-90	2011
Hatin W, Nur-Shafawati A, Zahri M, Xu S, Jin L, Tan S-G, Rizman-Idid M, Zifalil, B, <u>Gojobori T</u> , and others.	Gene dosage imbalance of human chromosome 21 in mouse embryonic stem cells differentiating to neurons.	PLoS One.	6(4)	e18312	2011
Weng L, Kohara M, <u>Wakita T</u> , Shimotohno K, Toyoda T.	Detergent-induced activation of the hepatitis C virus genotype 1b RNA polymerase.	Gene.	496(2)	79-87.	2012
*Murayama A, Kato T, Akazawa D, Sugiyama N, Date T, Masaki T, Nakamoto S, <u>Tanaka Y</u> , <u>Mizokami M</u> , <u>Yokosuka O</u> , Nomoto A, <u>Wakita T</u> .	Production of Infectious Chimeric Hepatitis C Virus Genotype 2b Harboring Minimal Regions of JFH-1.	J Virol.	86(4)	2143-52.	2012
Salim MT, Aoyama H, Sugita K, Watashi K, <u>Wakita T</u> , Hamasaki T, Okamoto M, Urata Y, Hashimoto Y, Baba M.	Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives.	Biochem Biophys Res Commun.	415(4)	714-9.	2011
*Sugiyama M, <u>Tanaka Y</u> , <u>Wakita T</u> , Nakanishi M, <u>Mizokami M</u> .	Genetic Variation of the IL-28B Promoter Affecting Gene Expression.	PLoS One.	6(10)	e26620.	2011
*Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, <u>Wakita T</u> , Meurs EF.	Hepatitis C virus reveals a novel early control in acute immune response.	PLoS Pathog.	7(10)	e1002289.	2011
Okamoto Y, Masaki T, Murayama A, Munakata T, Nomoto A, Nakamoto S, <u>Yokosuka O</u> , Watanabe H, <u>Wakita T</u> , Kato T.	Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2.	Biochem Biophys Res Commun.	410(3)	404-9.	2011
Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, Suzuki T, <u>Wakita T</u> .	Production and characterization of HCV particles from serum-free culture.	Vaccine.	29(29-30)	4821-8.	2011

*Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, Chayama K, Choi Y, Krawczynski K, Liang TJ, <u>Wakita T</u> , Kato T.	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis.	Hepatology.	54(2)	425-33.	2011
Aly HH, Oshiumi H, Shime H, Matsumoto M, <u>Wakita T</u> , Shimotohno K, Seya T.	Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV).	PLoS One.	6(6)	e21284.	2011
*Tamada Y, <u>Yatsuhashi H</u> , Masaki N, Nakamuta M, Mita E, Komatsu T, Watanabe Y, Muro T, Shimada M, Hijioka T, Satoh T, Mano Y, Komeda T, Takahashi M, Kohno H, Ota H, Hayashi S, Miyakawa Y, Abiru S, Ishibashi H.	Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B.	Gut.			2011 [Epub ahead of print]
八橋 弘, 長岡進矢, 阿比留正剛	B型肝炎に対するIFN治療	総合臨牀	60(1)	81-86	2011
八橋 弘, 長岡進矢, 玉田陽子	B型急性肝炎の動向と診断・治療	日本臨牀	69(増4)	440-445	2011
八橋 弘	感染に由来するヒトの腫瘍-その現状と対策, B型肝炎ウイルスと肝細胞癌	臨床と微生物	38(3)	27-33	2011
八橋 弘, 長岡進矢	ウイルス肝炎・治療/どのように実際の治療をすすめるか, HBワクチンの今後-現状と将来-	Medical Practice	28(8)	1449-1452	2011
* <u>Matsumoto A</u> , Tanaka E, Morita S, Yoshizawa K, Umemura T, Joshiita S	Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection.	J Gastroenterol.	in press		2012
Yoshizawa K, <u>Matsumoto A</u> , Ichijo T, Umemura T, Joshiita S, Komatsu M, Tanaka N, Tanaka E, Ota M, Katsuyama Y, Kiyosawa K, Abe M, Onji M.	Long-term outcome of Japanese patients with type 1 autoimmune hepatitis.	Hepatology	in press		2012
Wu S, Fukai K, Imazeki F, Arai M, Kanda T, Yonemitsu Y, <u>Yokosuka O</u> .	Initial virological response and viral mutation with adefovir dipivoxil added to ongoing Lamivudine therapy in Lamivudine-resistant chronic hepatitis B.	Dig Dis Sci.	56(4)	1207-14.	2011

*Bekku D, Arai M, Imazeki F, Yonemitsu Y, Kanda T, Fujiwara K, Fukai K, Sato K, Itoga S, Nomura F, <u>Yokosuka O.</u>	Long-term follow-up of patients with hepatitis B e antigen negative chronic hepatitis B.	J Gastroenterol Hepatol.	26(1)	122-8.	2011
Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.	Scand J Gastroenterol	46(9)	1111-7.	2011
*Wu S, Kanda T, Imazeki F, Nakamoto S, Shirasawa H, <u>Yokosuka O.</u>	Nuclear receptor mRNA expression by HBV in human hepatoblastoma cell lines.	Cancer Lett.	312(1)	33-42.	2011
Togo S, Arai M, Tawada A, Chiba T, Kanda T, Fujiwara K, Imazeki F, <u>Yokosuka O.</u>	Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B.	J Viral Hepat.	18(10)	e508-15.	2011
Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Arai M, Fujiwara K, Goto N, Imazeki F, <u>Yokosuka O.</u>	Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.	Int J Med Sci.	9	27-32	2012
Nakayama N, Oketani M, Kawamura Y, Inao M, Nagoshi S, Fujiwara K, Tsubouchi H, <u>Mochida S.</u>	Novel Classification of Acute Liver Failure through Clustering Using a Self-Organizing Map: Usefulness for Prediction of the Outcome.	J Gastroenterol	46	1127-1135	2011
<u>Mochida S.</u> , Takikawa Y, Nakayama N, Oketani M, Naiki T, Yamagishi Y, Ichida T, Tsubouchi H.	Diagnostic Criteria of Acute Liver Failure: A Report by the Intractable Hepato-Biliary Diseases Study Group of Japan.	Hepatol Res	41	805-812	2011
Naiki T, Nakayama N, <u>Mochida S.</u> , Oketani M, Takikawa H, Suzuki K, Tada S, Yano K, Ichida T, Moriwaki H, Tsubouchi H and the Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labor, and Welfare of Japan.	Scoring System as a Useful Model to Predict the Outcome of Patients with Acute Liver Failure: Application to Indication Criteria for Liver transplantation.	Hepatol Res	42	68-75	2012

<u>持田 智</u> , 滝川康裕, 中山伸朗, 桶谷 真, 内木隆文, 山岸由幸, 市田隆文, 坪内博仁.	我が国における「急性肝不全」の概念、診断基準の確立：厚生労働省科学研究費補助金（難治性疾患克服研究事業）「難治性の肝・胆道疾患に関する調査研究」班、ワーキンググループ-1、研究報告。	肝臓	52	393-398	2011
Yoshimi A, Yamamoto G, Goto T, Koike K , Kurokawa M	Hepatocellular carcinoma in cirrhotic liver with graft-versus-host disease	Ann Hematol		2012 Feb 9.[Epub ahead of print]	
Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, Ikeda H, Akahane M, Shiina S, Omata M, Yoshida H, Koike K	Value of post-vascular phase (Kupffer imaging) by contrast-enhanced ultrasonography using Sonazoid in the detection of hepatocellular carcinoma	J Gastroenterol		2011 Dec 27. [Epub ahead of print]	
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K	Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors	Am J Gastroenterol		2011 Dec 13. doi: 10.1038/ajg.2011.425. [Epub ahead of print]	
Ohki T, Tateishi R, Akahane M, Shiina S, Yamashiki N, Mikami S, Enooku K, Goto E, Masuzaki R, Kondo Y, Goto T, Inoo S, Ohtomo K, Omata M, Yoshida H, Koike K	Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial	Hepatol Int		2011 Aug 31. [Epub ahead of print]	
Enooku K, Tateishi R, Kanai F, Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, Koike K	Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times	J Gastroenterol		2011 Sep 21. [Epub ahead of print]	
Takata A, Otsuka M, Kogiso T, Kojima K, Yoshikawa T, Tateishi R, Kato N, Shiina S, Yoshida H, Omata M, Koike K	Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines.	Hepatol Int		2011 Feb 6. [Epub ahead of print]	
Inoue H, Yamazaki S, Shimizu M, Uozaki H, Goto T, Ohnishi S, Koike K	Liver injury induced by the Japanese herbal drug kamishoyosan	Gastroenterol Hepatol (NY)	7(10)	692-695	2011

Arano T, Nakagawa H, Tateishi R, Ikeda H, Uchino K, Enooku K, Goto E, Masuzaki R, Asaoka Y, Kondo Y, Goto T, Shiina S, Omata M, Yoshida H, <u>Koike K</u>	Serum level of adiponectin and the risk of liver cancer development in chronic hepatitis C patients	Int J Cancer	129	2226-2235	2011
Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S, <u>Koike K</u> , Omata M	Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation	Hepatol Int	5(3)	767-773	2011
*Taguwa S, Kambara H, Fujita N, Noda T, Yoshimori T, <u>Koike K</u> , Moriishi K, Matsuura Y	Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus	J Virol	85	13185-13194	2011
Kudo Y, <u>Tanaka Y</u> , Tateishi K, Yamamoto K, Yamamoto S, Mohri D, Isomura Y, Seto M, Nakagawa H, Asaoka Y, Tada M, Ohta M, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Maeda S, Shiina S, Yoshida H, Nakajima O, Kanai F, Omata M, <u>Koike K</u>	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway	J Hepatol	55(6)	1400-1408	2011
Ishizaka N, Hongo M, Sakamoto A, Saito K, Furuta K, <u>Koike K</u>	Liver lipid content is reduced in rat given 7-day administration of angiotensin II	J Renin Angiotensin Aldosterone Syst	12(4)	462-468	2011
Bertot LC, Sato M, Tateishi R, Yoshida H, <u>Koike K</u>	Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review	Eur Radiol	21(12)	462-468	2011
Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Yoshida H, Aoki T, Hasegawa K, Akahane M, Ohtomo K, Fukayama M, <u>Koike K</u> , Kokudo N	Diagnostic accuracy of α -fetoprotein and des- γ -carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates	Hepatol Res	41(12)	1199-1207	2011
Fujinaga H, Tsutsumi T, Yotsuyanagi H, Moriya K, <u>Koike K</u>	Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species	Oncology	Suppl 1	11-17	2011

*Ikeda H, Tateishi R, Enooku K, Yoshida H, Nakagawa H, Masuzaki R, Kondo Y, Goto T, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K , Yatomi Y	Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C	Cancer Epidemiol Biomarkers Prev	20(10)	2204-2211	2011
Watanabe S, Enomoto N, Koike K , Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M ; PERFECT Study Group.	Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.	Hepatol Res	41(10)	955-964	2011
Otsuka M, Takata A, Yoshikawa T, Kojima K, Kishikawa T, Shibata C, Takekawa M, Yoshida H, Omata M, Koike K	Receptor for Activated Protein Kinase C: Requirement for Efficient MicroRNA Function and Reduced Expression in Hepatocellular Carcinoma. PLoS One	PLoS One	6(9)	e24359.	2011
Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K	Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors.	Cancer	117(19)	4475-4483	2011
Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, Koike K	MicroRNA-22 and microRNA-140 suppress NF- κ B activity by regulating the expression of NF- κ B coactivators	Biochem Biophys Res Commun	411(4)	826-831	2011
Wakita T , Suzuki T , Evans MJ, Shimotohno K, Chayama K, Matsuura Y, Hijikata M, Moriishi K, Seya T, Enomoto N, Koike K , Kato N, Kanto T, Hotta H	Will There Be an HCV Meeting in 2020? Summary of the 17th International Meeting on Hepatitis C Virus and Related Viruses.	Gastroenterology	141(1)	e1-5	2011
Nakagawa H, Hirata Y, Takeda K, Hayakawa Y, Sato T, Kinoshita H, Sakamoto K, Nakata W, Hikiba Y, Omata M, Yoshida H, Koike K , Ichijo H, Maeda S	Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated MAPK	Hepatology	54(1)	185-195	2011

*Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K	MicroRNA122 is a key regulator of α -fetoprotein expression and biologically aggressive behavior of hepatocellular carcinoma	Nat Commun	2	338	2011
Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, Morisawa Y, Okugawa S, Kikuchi Y, Oka S, Kimura S, Yatomi Y, Makuuchi M, Kokudo N, Koike K	Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: Experience in a Single Center	Transplanta-tion	91(11)	1261-126 4	2011
Koshiyama A, Ichibangase T, Moriya K, Koike K , Yazawa I, Imai K	Liquid chromatographic separation of proteins derivatized with a fluorogenic reagent at cysteinyl residues on a non-porous column for differential proteomics analysis	J Chromatogr A	1218(22)	3447-345 2	2011
Nakagawa H, Ikeda H, Nakamura K, Ohkawa R, Masuzaki R, Tateishi R, Yoshida H, Watanabe N, Tejima K, Kume Y, Iwai T, Suzuki A, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Omata M, Igarashi K, Aoki J, Koike K , Yatomi Y	Autotaxin as a novel serum marker of liver fibrosis	Clin Chim Acta	412(13-14)	1201-120 6	2011
Kershenobich K, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K , Han K-H, Wallace CM, Zeuzem S, Negro F	Applying a systemapproach to forecast the total hepatitis Cvirusinfected population size:model validation using US data	Liver Int.	31(S2)	4-17	2011
Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, AlOmair A, Amarapurkar D, Chen C-H, Dou X, El Khayat H, elShazly M, Esmat G, Guan R, Han K-H, Koike K , Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.	Liver Int.	31(S2)	61-80	2011

Yasui K, Hashimoto E, Komorizono Y, Koike K , Arii S, Imai Y, Shima T, Kanbara Y, Saibara T, Mori T, Kawata S, Uto H, Takami S, Sumida Y, Takamura T, Kawanaka M, Okanoue T; The Japan NASH Study Group ,The Ministry of Health, Labour and Welfare of Japan.	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma	Clin Gastroenterol Hepatol	9(5)	428-433	2011
Koike K , Miyoshi H, Yotsyanagi H, Moriya K.	Effect of treatment with polynsaturated fatty acids on HCV-or diet-induced fatty liver	J Hepatol	54 6	1325-132	2011
Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, Kondo Y, Goto T, Ikeda H, Omata M, Koike K	Utility of contrast enhanced ultrasonography with sonazoid in radiofrequency ablation for hepatocellular carcinoma	J Gastroenterol Hepatol	26(4)	759-764	2011
Miyoshi H, Moriya K, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Fujinaga H, Goto K, Todoroki T, Suzuki T , Miyamura T, Matsuura Y, Yotsuyanagi H, Koike K .	Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein.	J Hepatol.	54(3)	432-8.	2011
Kondo Y, Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Goto E, Nakagawa H, Masuzaki R, Asaoka Y, Fujie H, Goto T, Omata M, Yoshida H, Koike K	Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient's prognosis	Liver Int	31	197-205	2011
*Kanamori H, Kawakami T, Effendi K, Yamazaki K, Mori T, Ebinauma H, Masugi Y, Du W, Nagasaka K, Ogiwara A, Kyono Y, Tanabe M, Saito H, Hibi T, Sakamoto M.	Identification by Differential Tissue Proteome Analysis of Talin-1 as a Novel Molecular Marker of Progression of HepatocellularCarcinoma.	Oncology	80	406-415	2011
*Tsuchiya K, Komuta M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Kuzuya T, Itakura J, Nakanishi H, Takahashi Y, Kurosaki M, Asahina Y, Enomoto N, Sakamoto M , Izumi N.	Expression of keratin19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.	Oncology	80	278-288	2011

Yamazaki K, Masugi Y, <u>Sakamoto M.</u>	Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor- β signaling in hepatocarcinogenesis.	Dig Dis.	29(3)	284-8	2011
Yokoo H, Yasuda J, Nakanishi K, Chuma M, Kamiyama T, Todo S, Hirohashi S, <u>Sakamoto M.</u>	Clinicopathological significance of nuclear factor- κ B activation in hepatocellular carcinoma.	Hepatol Res	41(3)	240-9	2011
Shirabe K, Toshima T, <u>Taketomi A</u> , Taguchi K, Yoshizumi T, Uchiyama H, Harimoto N, Kajiyama K, Egashira A, Maehara Y.	Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan..	Liver Int	31(9)	1366-1372	2011
Aishima S, Iguchi T, Fujita N, <u>Taketomi A</u> , Maehara Y, Tsuneyoshi M, Oda Y.	Histological and immunohistological findings in biliary intraepithelial neoplasia arising from a background of chronic biliary disease compared with liver cirrhosis of non-biliary aetiology.	Histopathology	59(5)	867-875	2011
*Sanefuji K, <u>Taketomi A</u> , Iguchi T, Sugimachi K, Ikegami T, Yamashita Y, Gion T, Soejima Y, Shirabe K, Maehara Y.	Significance of DNA Polymerase Delta Catalytic Subunit p125 Induced by Mutant p53 in the Invasive Potential of Human Hepatocellular Carcinoma.	Oncology	79(3-4)	229-237	2011
Kawate H, <u>Taketomi A</u> , Watanabe T, Nomura M, Kato M, Sakamoto R, Ikegami T, Soejima Y, Maehara Y, Takayanagi R.	Hypophosphatemic osteomalacia as a long-term complication after liver transplantation.	Transplantation	91(1)	e6-e8	2011
Shimoda S, Harada K, Niilo H, Shirabe K, <u>Taketomi A</u> , Maehara Y, Tsuneyama K, Nakanuma Y, Leung P, Ansari AA, Gershwin ME, Akashi K.	Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis.	Hepatology	53(4)	1270-1281	2011
Shirabe K, <u>Taketomi A</u> , Morita K, Soejima Y, Uchiyama H, Kayashima H, Ninomiya M, Toshima T, Maehara Y.	Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation.	Clin Transpl	25(5)	e491-e498	2011

Sugimachi K, Shirabe K, Taketomi A , Soejima Y, Iguchi T, Takeishi K, Toshima T, Aishima S, Tajima T, Maehara Y.	Prognostic significance of preoperative imaging in recipients of living donor liver transplantation for hepatocellular carcinoma.	Transplantation	91(5)	570-574	2011
Uchiyama H, Mano Y, Taketomi A , Soejima Y, Yoshizumi T, Ikegami T, Shirabe K, Maehara Y.	Kinetics of anti-blood type isoagglutinin titers and B lymphocytes in ABO-incompatible living donor liver transplantation with rituximab and plasma exchange.	Transplantation	92(10)	1134-1139	2011
Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A , Shirabe K, Maehara Y, Oda Y.	Different roles of S100P Overexpression in Intrahepatic Cholangiocarcinoma: Carcinogenesis of Perihilar Type and Aggressive Behavior of Peripheral Type.	Am J Surg Pathol	35(4)	590-598	2011
*H. Mbarek, H. Ochi, Y. Urabe, V. Kumar, M.Kubo,N. Hosono, A. Takahashi,Y. Kamatani, D. Miki, H. Abe, T. Tsunoda, N. Kamatani, K. Chayama, Y. Nakamura, K. Matsuda	A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population.	Human molecular genetics.	20(19)	3884-3892	2011
*J. Li, D. Yang, Y. He, M. Wang, Z. Wen, L. Liu, J. Yao, K.Matsuda , Y. Nakamura, J. Yu, X. Jiang, S. Sun, Q. Liu, Q. Song, M. Chen, H. Yang, F. Tang, X. Hu, J. Wang, Y. Chang, X. He, Y. Chen, J. Lin	Associations of HLA-DP variants with hepatitis B virus infection in southern and northern Han Chinese populations: a multicenter case-control study.	PloS one	6(8)	e24221	2011
*V.Kumar, N.Kato, Y.Urabe, A.akahashi, R.Muroyama, .Hosono, .Otsuka,R.Tateishi,M. Omata,H.Nakagawa, K.Koike , N.Kamatani, M.Kubo, Y.Nakamura, K.Matsuda ,	Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma.	Nature genetics	43(5)	455-458	2011
He D, Liu ZP, Honda M , Kaneko S, Chen L.	Coexpression network analysis in chronic hepatitis B and C hepatic lesion reveals distinct patterns of disease progression to hepatocellular carcinoma.	J Mol Cell Biol.	in press		2012
Mizuno H, Honda M , Shirasaki T, Yamashita T, Yamashita T, Mizukoshi E and Kaneko S.	Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma.	Liver International.	in press		2012

Sato Y, Ren XS, Harada K, Sasaki M, Morikawa H, Shiomi S, Honda M , Kaneko S, Nakanuma Y.	Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension: possible link to serum anti-endothelial cell antibodies.	Clin Exp Immunol.	167(3)	532-42	2012
Nakamura S, Kawai K, Takeshita Y, Honda M , Takamura T, Kaneko S, Matoba R, Matsubara K.	Identification of blood biomarkers of aging by transcript profiling of whole blood.	Biochem Biophys Res Commun.	Epub ahead of print.		2012
Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M , Kaneko S.	Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma.	Oncology.	81(5-6)	281-290	2011
*Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M , Okada SI, Asahina Y, Izumi N, Honda M , Kaneko S, Enomoto N.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.	Hepatol Int.	Epub ahead of print		2011
Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, Kagaya T, Yamashita T, Honda M , Kaneko S.	Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.	Hepatology.	53(4)	1206-16	2011
* Honda M , Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T , Wakita T , Kaneko S; Hokuriku Liver Study Group.	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.	Gastroenterology.	141(1)	128-40	2011
Yamashita T, Honda M , Kaneko S.	Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection.	J Gastroenterol Hepatol.	26(6)	960-4	2011

Kurosaki M, <u>Tanaka Y</u> , <u>Nishida N</u> , Sakamoto N, Enomoto N, <u>Honda M</u> , Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, <u>Sakamoto M</u> , Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, <u>Tokunaga K</u> , Izumi N, Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol.	54(3)	439-48	2011
Sunagozaka H, <u>Honda M</u> , Yamashita T, Nishino R, Takatori H, Arai K, Yamashita T, Sakai Y, Kaneko S.	Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma.	Int J Cancer.	129(7)	1576-85	2011
Saeed M, Suzuki R, Watanabe N, Masaki T, Tomonaga M, Muhammad A, Kato T, Matsuura Y, Watanabe H, <u>Wakita T</u> , <u>Suzuki T</u> .	Role of the endoplasmic reticulum-associated degradation (ERAD) pathway in degradation of hepatitis C virus envelope proteins and production of virus particles.	J Biol Chem	286 (43)	37264-37 273	2011
Yamamoto M, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, <u>Wakita T</u> , <u>Suzuki T</u> .	Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus.	J Gen Virol	92	2082-208 7	2011
Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, <u>Suzuki T</u> , <u>Wakita T</u>	Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.	Vaccine	29	4821-482 8	2011
Wen X, Abe T, Kukihara H, Taguwa S, Mori Y, Tani H, Kato N, <u>Suzuki T</u> , Tatsumi M, Moriishi K, Matsuura Y.	Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.	PLoS One.	6	E15967	2011
Watanabe N, Aizaki H, Matsuura T, Kojima S, <u>Wakita T</u> , <u>Suzuki T</u> .	Hepatitis C virus RNA replication in human stellate cells regulates gene expression of extracellular matrix-related molecules.	Biochem Biophys Res Commun.	407	135-140	2011

*Inoue Y, Aizaki H, Hara H, Matsuda M, Ando T, Shimoji T, Masaki T, Shoji I, Homma S, Matsuura Y, Miyamura T, <u>Wakita T</u> , <u>Suzuki T</u> .	Chaperonin TRiC/CCT participates in replication of hepatitis C virus genome via interaction with the viral NS5B protein.	Virology	410	38-47	2011
Iwasaki Y, Mori K, Ishii K, Maki N, Iijima S, Yoshida T, Okabayashi S, Katakai Y, Lee Y.J, Saito A, Funai H, Kimura N, Ageyama N, Yoshizaki S, <u>Suzuki T</u> , Yasutomi Y, Miyamura T, Kannagi M and Akari H	Long-term persistent GBV-B infection and development of a chronic and progressive hepatitis C-like disease in marmosets.	Front Microbiol.	2	240	2011
*Sa-Nguanmoo P, <u>Tanaka Y</u> , Ratanakorn P, Sugiyama M, Murakami S, Payungporn S, Sommanustweechai A, <u>Mizokami M</u> , Poovorawan Y.	Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes.	Virus Res.	158(1-2)	209-15	2011
Matsuura K, <u>Tanaka Y</u> , Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, <u>Mizokami M</u> .	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial.	Hepatol Res.	41(6)	505-511	2011
* <u>Matsumoto A</u> , Tanaka E, Suzuki Y, Kobayashi M, <u>Tanaka Y</u> , Shinkai N, Hige S, <u>Yatsuhashi H</u> , Nagaoka S, Chayama K, Tsuge M, <u>Yokosuka O</u> , Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.	Hepatol Res.	42(2)	139-149	2012

*IV.研究成果の別刷あり

IV. 研究成果の刊行物・別刷